Keenova Therapeutics Closes Sale of Percocet/Endocet Businesses for ~$250M

What Happened Keenova Therapeutics plc announced it closed the previously disclosed sale of its Percocet and Endocet businesses (the Business) to Par Health, Inc. on July 31, 2026. The total consideration is expected to be approximately $250.0 million, consisting of a $25.0 million upfront purchase price (subject to customary cash, debt and working capital adjustments) plus quarterly cash earnout payments tied to the Business’s gross profit over five years. After closing and completion of related transition services, Keenova will no longer market, manufacture or distribute opioid products.

Key Details

• Upfront purchase price: $25.0 million, subject to customary adjustments for cash, debt and working capital.
• Total expected consideration: approximately $250.0 million, including quarterly earnouts over five years.
• Buyer: Par Health, Inc.; closing date: July 31, 2026.
• Post-closing: Keenova will exit opioid product marketing, manufacturing and distribution after transition services are completed.

Why It Matters This divestiture materially changes Keenova’s product portfolio by removing its opioid business, which may affect future revenue mix and margins. The transaction provides immediate cash consideration and potential future cash inflows through earnouts, but those earnouts depend on the Business’s future gross profit and are therefore uncertain. The company’s filing also notes that expected totals are forward‑looking and subject to risks described in its SEC filings (including its 2025 Form 10‑K). Investors should watch for updates on actual received payments, any adjustments to the upfront price, and disclosures about the impact on revenue and profitability.